Table 2.
Detailed clinical score data for the experiments shown in Fig 6.
| Phase of EAMG | Group | Clinical scores (affected rats/total in group) | EAMG Incidence | |||||
|---|---|---|---|---|---|---|---|---|
| 0–1 | 1–2 | 2–3 | 3–4 | Deaths | Mean | |||
| Acute (day 10) (before treatment) | EAMG control | 1/12 | 4/12 | 6/12 | 1/12 | 0/12 | 1.63 | 11/12 |
| Treated with extracellular and cytoplasmic domains | 2/12 | 4/12 | 5/12 | 1/12 | 0/12 | 1.63 | 10/12 | |
| Treated with cytoplasmic domains | 0/11 | 7/11 | 3/11 | 1/11 | 0/11 | 1.59 | 11/11 | |
| Chronic (day 49) (after treatment) | EAMG control | 0/12 | 3/12 | 2/12 | 1/12 | 6/12 | 2.92 | 12/12 |
| Treated with extracellular and cytoplasmic domains | 5/12 | 4/12 | 2/12 | 1/12 | 0/12 | 0.96 | 7/12 | |
| Treated with cytoplasmic domains | 8/11 | 2/11 | 0/11 | 1/11 | 0/11 | 0.50 | 3/11 | |